Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Protoplasma
2017 May 01;2543:1163-1173. doi: 10.1007/s00709-016-1060-1.
Show Gene links
Show Anatomy links
Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W, Zhang H, Wang X, Patterson J, Winter P, Graham K, Ghosh S, Lee JC, Katsetos CD, Mackey JR, Tuszynski JA, Wong GK, Ludueña RF.
???displayArticle.abstract???
Tubulin is the target for very widely used anti-tumor drugs, including Vinca alkaloids, taxanes, and epothilones, which are an important component of chemotherapy in breast cancer and other malignancies. Paclitaxel and other tubulin-targeting drugs bind to the β subunit of tubulin, which is a heterodimer of α and β subunits. β-Tubulin exists in the form of multiple isotypes, which are differentially expressed in normal and neoplastic cells and differ in their ability to bind to drugs. Among them, the βIII isotype is overexpressed in many aggressive and metastatic cancers and may serve as a prognostic marker in certain types of cancer. The underpinning mechanisms accounting for the overexpression of this isotype in cancer cells are unclear. To better understand the role of β-tubulin isotypes in cancer, we analyzed over 1000 clones from 90 breast cancer patients, sequencing their β-tubulin isotypes, in search of novel mutations. We have elucidated two putative emerging molecular subgroups of invasive breast cancer, each of which involve mutations in the βI-, βIIA-, or βIVB isotypes of tubulin that increase their structural, and possibly functional, resemblance to the βIII isotype. A unifying feature of the first of the two subgroups is the mutation of the highly reactive C239 residue of βI- or βIVB-tubulin to L239, R239, Y239, or P239, culminating in probable conversion of these isotypes from ROS-sensitive to ROS-resistant species. In the second subgroup, βI, βIIA, and βIVB have up to seven mutations to the corresponding residues in βIII-tubulin. Given that βIII-tubulin has emerged as a pro-survival factor, overexpression of this isotype may confer survival advantages to certain cancer cell types. In this mini-review, we bring attention to a novel mechanism by which cancer cells may undergo adaptive mutational changes involving alternate β-tubulin isotypes to make them acquire some of the pro-survival properties of βIII-tubulin. These "hybrid" tubulins, combining the sequences and/or properties of two wild-type tubulins (βIII and either βI, βIIA, or βIVB), are novel isotypes expressed solely in cancer cells and may contribute to the molecular understanding and stratification of invasive breast cancer and provide novel molecular targets for rational drug development.
Amos,
How Taxol stabilises microtubule structure.
1999, Pubmed
Amos,
How Taxol stabilises microtubule structure.
1999,
Pubmed Anders,
Dominant-lethal alpha-tubulin mutants defective in microtubule depolymerization in yeast.
2001,
Pubmed Bai,
Mapping the binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354.
2000,
Pubmed Bai,
Identification of the cysteine residue of beta-tubulin alkylated by the antimitotic agent 2,4-dichlorobenzyl thiocyanate, facilitated by separation of the protein subunits of tubulin by hydrophobic column chromatography.
1989,
Pubmed Banerjee,
Interactions of a bicyclic analog of colchicine with beta-tubulin isoforms alphabeta(II), alphabeta(III) and alphabeta(IV).
1997,
Pubmed Banerjee,
Interaction of desacetamidocolchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers alpha beta II, alpha beta III, and alpha beta IV.
1994,
Pubmed Banerjee,
Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain.
1992,
Pubmed Bastani,
A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status.
2013,
Pubmed Bowne-Anderson,
Microtubule dynamic instability: a new model with coupled GTP hydrolysis and multistep catastrophe.
2013,
Pubmed Brown,
Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer.
2001,
Pubmed Bustin,
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.
2009,
Pubmed Churchill,
The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments.
2015,
Pubmed De Donato,
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
2012,
Pubmed Derry,
Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.
1997,
Pubmed Dong,
Disulfide bonds required to assemble functional von Willebrand factor multimers.
1994,
Pubmed Dráberová,
Expression of class III beta-tubulin in normal and neoplastic human tissues.
1998,
Pubmed Dráberová,
Class III beta-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity.
2008,
Pubmed Dumontet,
Microtubule-binding agents: a dynamic field of cancer therapeutics.
2010,
Pubmed Dumontet,
Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
2009,
Pubmed Egevad,
Beta-tubulin III expression in prostate cancer.
2010,
Pubmed Ewing,
Base-calling of automated sequencer traces using phred. II. Error probabilities.
1998,
Pubmed Ewing,
Base-calling of automated sequencer traces using phred. I. Accuracy assessment.
1998,
Pubmed Ferrandina,
Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome.
2007,
Pubmed Ferrandina,
Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.
2006,
Pubmed Gan,
Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
2007,
Pubmed Garland,
Kinetics and mechanism of colchicine binding to tubulin: evidence for ligand-induced conformational change.
1978,
Pubmed Gigant,
Structural basis for the regulation of tubulin by vinblastine.
2005,
Pubmed Goldspiel,
Clinical overview of the taxanes.
1997,
Pubmed Gordon,
Consed: a graphical tool for sequence finishing.
1998,
Pubmed Gordon,
Automated finishing with autofinish.
2001,
Pubmed Herbert,
A cis-acting sequence homologous to the yeast filamentation and invasion response element regulates expression of a pectinase gene from the bean pathogen Colletotrichum lindemuthianum.
2002,
Pubmed Jordan,
Microtubules and actin filaments: dynamic targets for cancer chemotherapy.
1998,
Pubmed Karki,
βIII-Tubulin: biomarker of taxane resistance or drug target?
2013,
Pubmed Katsetos,
Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
2011,
Pubmed Katsetos,
Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
2009,
Pubmed Katsetos,
Class III beta-tubulin isotype (beta III) in the adrenal medulla: I. Localization in the developing human adrenal medulla.
1998,
Pubmed Katsetos,
Tubulins as therapeutic targets in cancer: from bench to bedside.
2012,
Pubmed Katsetos,
Emerging microtubule targets in glioma therapy.
2015,
Pubmed Katsetos,
Differential localization of class III, beta-tubulin isotype and calbindin-D28k defines distinct neuronal types in the developing human cerebellar cortex.
1993,
Pubmed Katsetos,
Class III beta-tubulin in human development and cancer.
2003,
Pubmed Katsetos,
Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology.
2003,
Pubmed Kavallaris,
Microtubules and resistance to tubulin-binding agents.
2010,
Pubmed Khan,
Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain.
2003,
Pubmed Khan,
Phosphorylation of beta III-tubulin.
1996,
Pubmed Leandro-García,
Tumoral and tissue-specific expression of the major human beta-tubulin isotypes.
2010,
Pubmed Lek,
Analysis of protein-coding genetic variation in 60,706 humans.
2016,
Pubmed Levallet,
High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
2012,
Pubmed Little,
Structural differences between brain beta 1- and beta 2-tubulins: implications for microtubule assembly and colchicine binding.
1985,
Pubmed Liu,
A new class of regulatory genes underlying the cause of pear-shaped tomato fruit.
2002,
Pubmed Lopata,
In vivo microtubules are copolymers of available beta-tubulin isotypes: localization of each of six vertebrate beta-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens.
1987,
Pubmed Löwe,
Refined structure of alpha beta-tubulin at 3.5 A resolution.
2001,
Pubmed Luchko,
Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes.
2008,
Pubmed Ludueña,
beta 2-Tubulin, a form of chordate brain tubulin with lesser reactivity toward an assembly-inhibiting sulfhydryl-directed cross-linking reagent.
1982,
Pubmed Ludueña,
Multiple forms of tubulin: different gene products and covalent modifications.
1998,
Pubmed Mariani,
Class III β-tubulin in normal and cancer tissues.
2015,
Pubmed Mayadas,
Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly.
1992,
Pubmed McCarroll,
betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.
2010,
Pubmed McCarroll,
TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.
2015,
Pubmed Minotti,
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
1999,
Pubmed Mitchison,
Dynamic instability of microtubule growth.
,
Pubmed Mooberry,
Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
1999,
Pubmed Müller-Reichert,
Structural changes at microtubule ends accompanying GTP hydrolysis: information from a slowly hydrolyzable analogue of GTP, guanylyl (alpha,beta)methylenediphosphonate.
1998,
Pubmed Nicolini,
Metastatic breast cancer: an updating.
2006,
Pubmed Nogales,
Structure of tubulin at 6.5 A and location of the taxol-binding site.
1995,
Pubmed Palanivelu,
Interactions of the tau-tubulin-vinblastine complex with colchicine, podophyllotoxin, and N,N'-ethylenebis(iodoacetamide).
1982,
Pubmed Pamula,
The structured core of human β tubulin confers isotype-specific polymerization properties.
2016,
Pubmed Panda,
Microtubule dynamics in vitro are regulated by the tubulin isotype composition.
1994,
Pubmed Parker,
Microtubules and their role in cellular stress in cancer.
2014,
Pubmed Pryor,
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity.
2002,
Pubmed Punnonen,
Antioxidant enzyme activities and oxidative stress in human breast cancer.
1994,
Pubmed Raspaglio,
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.
2008,
Pubmed Ravelli,
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.
2004,
Pubmed Ray,
Lipid peroxidation, free radical production and antioxidant status in breast cancer.
2000,
Pubmed Sartorelli,
Cancer chemotherapy.
1969,
Pubmed Schwarz,
Beta-tubulin isotypes purified from bovine brain have different relative stabilities.
1998,
Pubmed Sève,
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
2008,
Pubmed Sharma,
Use of N,N'-polymethylenebis(iodoacetamide) derivatives as probes for the detection of conformational differences in tubulin isotypes.
1994,
Pubmed Shelden,
Observation and quantification of individual microtubule behavior in vivo: microtubule dynamics are cell-type specific.
1993,
Pubmed Snyder,
The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density.
2001,
Pubmed Terry,
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.
2009,
Pubmed Torin Huzil,
Computational design and biological testing of highly cytotoxic colchicine ring A modifications.
2010,
Pubmed Tseng,
Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.
2010,
Pubmed Tsourlakis,
βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
2014,
Pubmed Vásquez-Vivar,
Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin.
1997,
Pubmed Wilmes,
Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
2011,
Pubmed Yeh,
Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.
2016,
Pubmed
